Alpha-1-antitrypsin augmentation therapy in deficient individuals enrolled in the Alpha-1 Foundation DNA and Tissue Bank | Zendy

Adriano R. Tonelli | Zendy; Farshid N. Rouhani | Zendy; Ning Li | Zendy; P Schreck | Zendy; Mark Brantly | Zendy

Open Access

Alpha-1-antitrypsin augmentation therapy in deficient individuals enrolled in the Alpha-1 Foundation DNA and Tissue Bank

Author(s) -

Adriano R. Tonelli,

Farshid N. Rouhani,

Ning Li,

P Schreck,

Mark Brantly

Publication year - 2009

Publication title -

international journal of copd

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.394

H-Index - 67

eISSN - 1178-2005

pISSN - 1176-9106

DOI - 10.2147/copd.s8577

Subject(s) - medicine , alpha 1 antitrypsin deficiency , copd , alpha (finance) , gastroenterology , surgery , construct validity , patient satisfaction

Intravenous augmentation therapy with purified intravenous alpha-1 antitrypsin replaces the deficient protein and is the only currently approved treatment for alpha-1 antitrypsin deficiency (AATD) related lung disease. While augmentation therapy has been available for more than 20 years, there are a limited number of studies evaluating the effect of augmentation on lung function.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research